Introduction
There is a growing population of adults with congenital heart disease (ACHD) at increased risk of premature morbidity and mortality. 1, 2 Clinical care for these patients focuses on either identifying and intervening on residual haemodynamically impactful anatomic lesions or responding to incident clinical events, such as arrhythmia or heart failure, when they occur.
Chronic low-level inflammation has increasingly been implicated in atherosclerotic cardiovascular disease, and recent evidence demonstrates that medications targeting the inflammatory response can prevent cardiovascular events. 3 Measurement of circulating C-reactive protein (CRP), a liver-derived pentraxin with a central role in the innate immune response, is the favoured and most accessible approach to identifying individuals with heightened systemic inflammation. Standard CRP assays distinguish between markedly elevated and normal CRP levels, whereas more recently developed high-sensitivity CRP (hsCRP) assays can differentiate concentrations within the normal range, a key feature since even within this normal range, higher hsCRP is strongly associated with increased risk for cardiovascular events. This observation has been replicated in various populations, including men and women, those with and without known cardiovascular disease, and those with and without elevated cholesterol levels. [4] [5] [6] [7] [8] The role of measuring hsCRP in atherosclerotic cardiovascular risk assessment and management is a topic of ongoing debate, and only a subset of recent society guidelines define a role for routine assessment. [9] [10] [11] [12] While some have recommended hsCRP measurement to help guide preventive interventions in specific clinical circumstances, existing indications likely apply to a small subset of adults with CHD who tend to be relatively young. 9, 10 Little is known about the role of inflammation in the pathophysiology of CHD in adulthood, or the potential clinical usefulness of hsCRP measurement in this expanding population. In this study, we investigated the association of hsCRP levels with clinical characteristics and adverse outcomes in adults with CHD.
Methods

Study sample
We enrolled outpatients with CHD > _18 years old between 2012 and 2016 seen at Boston Children's or Brigham and Women's Hospitals. Details of the Boston ACHD Biobank have been published previously. 13 The study complied with the Declaration of Helsinki, was approved by Boston Children's Hospital's Institutional Review Board with a formal reliance agreement between the Partners HealthCare/Brigham and Women's Hospital and Boston Children's Hospital Institutional Review Boards, and informed consent was obtained from all subjects or their legally authorized representative.
Data collection and definitions
Demographic and clinical data were collected from the participants' medical records as previously described. 13 When possible, variables reflect testing from the day of baseline visit when hsCRP was measured. In the absence of intervening clinical intervention or events, we included data obtained within 2 years of sample collection. We classified CHD patients into different pathophysiological groups as detailed in the Supplementary material online. Patients were also classified on the basis of New York Heart Association functional class (NYHA FC) (I vs. > _II), presence of cyanosis (defined as resting arterial oxygen saturation <92%), diagnosis severity based on 32nd Bethesda consensus conference recommendations, which rely mainly on anatomical complexity with modification for additional characteristics (e.g. any defect associated with pulmonary vascular disease is classified as severely complex), 14 and presence of a singleventricle vs. bi-ventricular circulation. Estimated glomerular filtration rate (eGFR) was calculated using the creatinine-based Chronic Kidney Disease Epidemiology Collaboration equation. 15 
Measurement of high-sensitivity C-reactive protein
Blood was collected in a serum separator tube and allowed to clot for 30-60 min at room temperature, followed by centrifugation at 1300 g for 10 min at 4 C; hsCRP was measured from these fresh serum samples with a Cobas 8000 analyser using a latex particle-enhanced immunoturbidimetric assay (Roche Diagnostics, Indianapolis, IN, USA) by a Clinical Laboratory Improvement Amendments approved laboratory (LabCorp, Laboratory Corporation of America, Burlington, NC, USA). The assay's lower limit of detection is 0.1 mg/L; between-run coefficients of variation are 3.1% and 2.3% at mean values of 1.5 mg/L and 11.4 mg/L, respectively. Other laboratory testing was performed as described in a prior publication. 13 
Outcomes assessed
The primary outcome of interest was the combination of either all-cause mortality or non-elective cardiovascular hospitalization. Non-elective cardiovascular hospitalization was defined as overnight admission for heart failure, arrhythmia or symptoms of arrhythmia, thromboembolism, cerebral haemorrhage, or cardiovascular disease-specific events (e.g. hyperviscosity symptoms in Eisenmenger syndrome). All-cause mortality was also considered a primary outcome. Secondary outcomes of interest were: (i) worsening heart failure resulting in either hospitalization or initiation/intensification of diuretic therapy; (ii) the combination of either death or worsening heart failure; (iii) arrhythmia resulting in either hospitalization, electrical cardioversion, placement of a pacemaker/defibrillator, or initiation/change of antiarrhythmic medications; (iv) thromboembolism, such as myocardial infarction, ischaemic cerebrovascular accident, or pulmonary embolism resulting in hospitalization or a new therapy; (v) catheterization intervention; (vi) cardiac surgical intervention, or (vii) a combined outcome of any of the above.
Data analysis
Continuous hsCRP was natural log transformed for analysis. We also categorized hsCRP according to quartile based on the distribution of the underlying data. Continuous variables are presented as mean ± standard deviation (SD) for normally distributed variables or non-normally distributed variables for groups with sample size >100, and median (25th-75th percentile) for non-normally distributed variables otherwise. The twosided unpaired Student's t-test or Wilcoxon rank-sum test, as appropriate for distribution, was used to compare continuous variables. Fisher's exact test was used to analyse categorical variables between groups by hsCRP level as defined above. When comparing values across the four quartiles of hsCRP, continuous and categorical variables were assessed with tests for trend, respectively ANOVA for linear trend and the Mantel-Haenszel extension of the v 2 test. Survival analyses focus on comparison between the top hsCRP quartile and the other quartiles combined, as the top quartile was associated with a substantially higher risk of adverse outcomes, while the 2nd and 3rd were associated with only marginally increased risk, and also because the cut-off for the highest quartile mirrors a clinically relevant category (i.e. >3 mg/L, a value often used in other clinical contexts). We also present data on hsCRP as a continuous, natural log-transformed variable, with results reported per one SD increase. The log-rank test was used to perform univariate survival analysis, comparing the top hsCRP quartile to the bottom three. Timeto-event analyses were conducted from the date of biospecimen collection to the date of the first clinical event, with censoring of event-free individuals at the most recent clinical follow-up date when event status was known. Multivariable survival analysis was performed using Cox regression, with forward selection including all variables associated with log hsCRP at P < 0. Given the potential for overfitting given the number of deaths, we repeated the all-cause mortality analysis using models adjusting for every set of two of the four variables listed above; the findings were consistent and only the overall model results are presented. In addition to this model defined by automated forward selection, we repeated the analysis adjusting for a set of investigator-defined variables likely to be associated with outcomes and hsCRP: age, sex, body mass index (BMI), NYHA FC, diagnosis severity, and Fontan vs. bi-ventricular circulation. To determine whether the predictive value of hsCRP persists beyond an initial short time after measurement, we performed a 1 year event-free survival landmark analysis, conditional on patients surviving at least 1 year after hsCRP measurement without the clinical outcome being analysed. The assumption of proportional hazards was assessed for each analysis and there was no apparent violation. High-sensitivity C-reactive protein was also analysed as a continuous variable using restricted cubic splines to assess for a non-linear relationship between hsCRP and clinical outcomes. Analyses were performed with SAS 9.4 (SAS Institute, Inc., Cary, NC, USA), R version 3.4.1, and GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA). A two-sided P-value <0.05 was considered statistically significant.
Results
Description of the cohort
Over the study period, 753 patients were enrolled, of whom 46 did not have blood collected (Supplementary material online, Figure S1 ). The cohort analysed included 707 adults with CHD, 50.6% male, with average age of 38.5 ± 13.5 years ( Table 1 Demographic and clinical characteristics of the study sample are presented, categorized by hsCRP quartile. Continuous variables are presented as mean ± SD. Categorical variables are presented as n (% of the column total). The ANOVA test for linear trend and the Mantel-Haenszel extension of the v 2 test for trend were used to analyse trends across the four quartiles for continuous and categorical variables, respectively. Cyanosis was defined as resting oxygen saturation <92%. Chronic kidney disease was defined as estimated glomerular filtration rate <60 mL/min/1.73 m 2 . Missing data: n = 4 for NYHA FC, n = 5 for BMI, n = 3 for pacemaker and ICD, and n = 73 for oxygen saturation/cyanosis status. BMI, body mass index; hsCRP, high-sensitivity C-reactive protein; ICD, implantable cardioverter-defibrillator; NYHA, New York Heart Association. (n = 117, 16.6%), simple shunt lesion without clinical sequelae (n = 78, 11.0%; clinical sequelae include heart failure, arrhythmia, or pulmonary hypertension), and transposition of the great arteries with a systemic right ventricle (n = 67, 9.5%). Comorbidities associated with increased atherosclerotic risk, such as diabetes and hyperlipidaemia were relatively uncommon ( Table 1) .
Cross-sectional analysis of C-reactive protein
Median hsCRP was 1.22 mg/L (25th-75th percentiles, 0.52-2.98). Older age, higher BMI, obstructive sleep apnoea, and the presence of diabetes mellitus were all associated with higher hsCRP, whereas other atherosclerotic risk factors were not ( Table 1) . Women had modestly higher hsCRP levels than men (median 1.34 vs. 1.11 mg/L, Wilcoxon P = 0.01).
Disease complexity/severity ( Table 1) was not related to elevated hsCRP. There was a statistically significant relationship between CHD diagnosis group and a baseline hsCRP in the top quartile (> _2.98 mg/L), but the distribution of hsCRP and prevalence of elevated hsCRP was similar for most groups (Figure 1 ; Supplementary material online, Figure S2 ).
There was a cross-sectional relationship between hsCRP and both markers of heart failure and a history of atrial arrhythmia ( Table 1 ; Supplementary material online, Table S1 ). Among women, the use of oral contraceptives or hormone replacement was associated with higher hsCRP (Supplementary material online, Table S1 ).
There was a strong relationship between higher hsCRP and lower peak V _ O 2 among the 499 patients who had a cardiopulmonary exercise test (median time from exercise testing to blood draw 0.1 years, interquartile range 0.0-1.4 years; n = 212 same day). Higher hsCRP was also associated with lower peak heart rate and higher V _ E:V _ CO 2 slope ( Table 2) .
Survival analysis
After a mean follow-up of 815 ± 536 days (median 763 days, 25th-75th percentiles 421-1, 230 days), 114 (16.1%) patients experienced the primary combined outcome, of whom 29 (4.1%) died. There was a stepwise increase in risk of the primary outcome with hsCRP quartile but only the highest quartile was associated with substantially and statistically significantly increased risk of the combined outcome of death or non-elective cardiovascular hospitalization [hazard ratio Figure 2 Kaplan-Meier cumulative incidence plots for adults with congenital heart disease, comparing highest high-sensitivity C-reactive protein quartile to the lower quartiles combined. The cumulative incidence of (A) either death or non-elective cardiovascular hospitalization and (B) all-cause mortality are shown. The numbers at risk for the relevant outcome at 365 day intervals are presented below the x axis. hsCRP, high-sensitivity C-reactive protein.
. Figure S3A ). Likewise, only those in the highest hsCRP quartile were at increased risk for all-cause mortality (HR = 1.64, 95% CI 0.30-8.97, P = 0.57; HR = 0.75, 95% CI 0.11-5.31, P = 0.77; HR = 9.03, 95% CI 2.11-38.6, P = 0.003, for the 2nd, 3rd, and 4th quartiles, respectively) (Supplementary material online, Figure S3B ).
Compared with the lower three hsCRP quartiles, those in the highest quartile (> _2.98 mg/L) were at increased risk for the combined outcome (n = 54/177, 30.5% vs. n = 60/530, 11.3%; HR = 3.26, 95% CI 2.25-4.70, P < 0.0001) and also for all-cause mortality (n = 21/156, 11.9% vs. n = 8/530, 1.5%; HR = 8.04, 95% CI 3.56-18.17, P < 0.0001) (Figure 2) . Adjusting for covariates identified using forward selection (NYHA FC, cyanosis, history of atrial arrhythmia, and eGFR), hsCRP in the highest quartile remained a significant predictor of both the combined outcome (adjusted HR = 2.00, 95% CI Among patients who underwent clinical cardiopulmonary exercise testing (n = 499/707, 70.6%), those with higher hsCRP tended to have lower peak V _ O 2 , whether indexed to body mass or as a percent of predicted values, as well as lower peak heart rate and higher V _ E:V _ CO 2 slope. Data are presented as mean ± SD. The ANOVA test for linear trend was used to compare the four quartiles. ANOVA, analysis of variance; b.p.m., beats per minute; hsCRP, high-sensitivity C-reactive protein; Q1-Q4, first through fourth quartiles of hsCRP; V _ E:V _ CO 2 , ratio of minute ventilation to carbon dioxide production; V _ O 2 , oxygen consumption. The relationship between hsCRP level and outcomes was also apparent when hsCRP was analysed as a continuous log-transformed variable (per þ1 SD, HR = 1.68, 95% CI 1.40-2.01, P < 0.0001; HR = 2.29, 95% CI 1.61-3.28, P < 0.0001 for combined outcome and all-cause mortality, respectively). As suggested by the quartile-based analysis, although those with the highest hsCRP levels had the highest risk, higher hsCRP was associated with a higher risk of adverse outcomes, whether the combined outcome ( Figure 3A or B) or all-cause mortality ( Figure 3C or D) , at any level of hsCRP.
The association between hsCRP and the combined outcome was largely consistent among various subgroups ( Table 3 ). The relationship was present in both sexes, but appeared weaker for women than men. The two-way interaction was marginally significant, though this was no longer the case after adjusting for oral hormone use. We repeated this analysis using sex-specific hsCRP quartiles. The cut-off for highest quartile was higher for women than men (3.39 vs. 2.35 mg/L). Using these sex-specific values, there remained a stronger association among men than women (HR = 4.02, 95% CI 2.45-6.60, P < 0.0001 vs. HR = 2.28, 95% CI 1.30-4.01, P = 0.004), but the difference was less prominent, and the two-way interaction was not significant (P = 0.13). Subgroup analyses did not include multivariable modelling or analysis of mortality as an outcome given the relatively small number of events in some subgroups. Elevated hsCRP was associated with all secondary outcomes except cardiac surgery (Figure 4) . The relationship between higher hsCRP and worsening heart failure, though, appeared to be stronger than for development of a clinically relevant arrhythmia.
Alternative causes of inflammation and sensitivity analyses
Documented chronic infections were uncommon: 11 hepatitis C, one human immunodeficiency virus, four Lyme disease, and no chronic mycobacterial infection. Likewise, few patients carried a rheumatologic diagnosis other than gout: five psoriasis, one mixed connective tissue disease, one rheumatoid arthritis, and one systemic lupus erythematosus. Further, few initial non-elective cardiovascular hospitalizations were related to infection, with five cases of subacute bacterial endocarditis or suspected endocarditis, one pacemaker infection, and one presentation with sepsis in the context of heart failure. None of these hospitalizations occurred within 30 days after hsCRP measurement. We repeated analyses after excluding those with hsCRP > _10.0 mg/L (n = 44), since such elevated levels could be due to acute infection and not reflective of chronic inflammation. The results were qualitatively equivalent (combined outcome adjusted HR = 1.81, 95% CI 1.18-2.79, P = 0.007; all-cause mortality adjusted HR = 3.92, 95% CI 1.60-9.61, P = 0.003). Likewise, excluding women using oestrogen-containing medications did not affect the results.
To confirm that elevated hsCRP was predictive of events beyond the immediate-term, we performed a 1 year event-free survival landmark analysis, conditional on survival to that point without an event (for all-cause mortality n = 553, for the combined outcome n = 516). The results were equivalent to the overall analysis (combined outcome unadjusted HR = 3.02, 95% CI 1.82-4.99, P < 0.0001; adjusted HR = 2.17, 95% CI 1.29-3.65, P = 0.004; all-cause mortality unadjusted HR = 8.99, 95% CI 1.86-16.96, P < 0.0001; adjusted HR = 5.61, 95% CI 1.86-16.96, P = 0.002) (Supplementary material online, Figure S4 ).
Discussion
In this prospective cohort study of 707 outpatient adults with CHD, we report that: (i) about a quarter of ACHD patients have hsCRP >3 mg/L; (ii) elevated hsCRP is associated with worse functional capacity and exercise performance as well as markers of clinical heart failure; and (iii) elevated hsCRP is an independent predictor of future cardiovascular events and all-cause mortality.
The prevalence of hsCRP >3 mg/L (rounded from 2.98 for simplicity and to allow comparison to existing literature) in our cohort is similar to the figure (30%) reported from a recent cross-sectional study of atherosclerotic risk factors in adults with CHD, and also approximates the prevalence of hsCRP >3 mg/L in the general adult population. 7, 8, 16 This cohort, however, is younger than most cohorts that have been used to derive adult population norms and hsCRP levels increase with age. High-sensitivity C-reactive protein has several features appealing for clinical and epidemiologic use. These include a long circulating half-life, long-term stability in frozen samples, insensitivity to recent food intake or circadian effects, and the availability of precise and inexpensive assays. 16 With acute infection, levels increase by orders of magnitude, well beyond normal variation, making it possible to identify outliers. Conversely, hsCRP levels tend to remain stable over time in the absence of acute infection, with within-person variability over time similar to systolic blood pressure and low-density lipoprotein (LDL) cholesterol. 7, 8 These characteristics, along with its strong prognostic power for identifying incident cardiovascular events independently of common risk markers in diverse populations, have led to a role in clinical risk stratification and decision-making. 10 There has been little research on hsCRP in ACHD. Eindhoven investigated high-sensitive troponin-T in adults with CHD. 17 In that cohort, there was no statistically significant relationship between high-sensitive troponin-T and hsCRP. Although there was a trend towards a higher prevalence of NYHA FC >I among those with higher hsCRP (18 vs. 9%, odds ratio 1.82, 95% CI 0.94-3.6), in contrast to our findings there was no suggestion of a relationship between hsCRP and loss of sinus rhythm. 17 Few studies have investigated whether hsCRP predicts clinical outcomes. Scognamiglio et al. studied a cohort of adults with CHD and pulmonary arterial hypertension; they found that higher CRP (using a conventional CRP assay with analytical range 1-250 mg/L) was associated with increased risk of mortality and a CRP >10 mg/L was linked to a >3.5-fold increased risk of death. 18 Miyamoto studied a number of circulating biomarkers in 103 patients with CHD, 61 of whom had single-ventricle Fontan circulation. 19 High-sensitivity C-reactive protein was associated with worse NYHA FC, greater cardiothoracic ratio, and also marginally with cardiovascular death. The associations observed between hsCRP in our cohort parallel those reported for the general population, including the inverse relationship with high-density lipoprotein cholesterol and albumin and positive associations with LDL cholesterol, and BMI. 7 We observed no association between hsCRP and history of coronary artery disease or cerebrovascular accident. This could be explained by the low prevalence of these diagnoses, greater use of medical therapy, or the high frequency of alternative, non-atherosclerotic pathophysiology for such events in CHD. For example, endocarditis and perioperative injury are relatively common causes of stroke in adults with CHD. We suspect the association between hsCRP and incident atherosclerotic events in adults with CHD is similar to the robust association between hsCRP and such events in other populations at low risk for atherosclerotic events. The increased risk in this young population with cardiovascular disease; however, is largely due to nonatherosclerotic causes and it appears that high hsCRP is predictive of these outcomes as well.
There was some heterogeneity in the relationship between hsCRP and adverse outcomes by sex, though the risk of adverse outcomes was markedly higher among both men and women in the highest hsCRP quartile. The concentration of hsCRP is, on average, modestly higher in pre-menopausal women than men, 20, 21 beyond the contribution of oestrogen-containing medications to increasing hsCRP Elevated hsCRP in the highest quartile was associated with increased risk of the combined outcome (death or non-elective cardiovascular hospitalization) consistently across subgroups. Whereas hsCRP was associated with outcome in both sexes, the relationship tended to be stronger in men than women, though the two-way interaction was not statistically significant after adjusting for oral hormone medication use. Likewise, whereas the relationship between hsCRP and outcome was less strong among patients with cyanosis, there was no significant interaction. Missing data: n = 4 for NYHA FC, n = 5 for BMI, and n = 73 for oxygen saturation/cyanosis status. BMI, body mass index; eGFR, estimated glomerular filtration rate using the creatinine-based Chronic Kidney Disease Epidemiology Collaboration equation; hsCRP, high-sensitivity C-reactive protein; NYHA FC, New York Heart Association functional class; Q4, highest/4th quartile of hsCRP.
a Adjusting for oestrogen use, HR for hsCRP Q4 vs. others among females = 2.44, 95% CI 1.39-4.29; P = 0.0019; two-way interaction P value 0.09. levels. We found hsCRP to be modestly higher among women in this cohort also. Sex-specific normal ranges have been used in some epidemiological studies, 21 though practice guidelines and intervention trials have applied a single sex-pooled cut-off value to indicate clinically relevant increased risk which may influence therapy. 10, 22 We primarily analysed the data using sex-pooled categories. The findings were similar when we applied sex-specific quartiles, though the difference between men and women did narrow. Therefore, while the sex-specific interpretation of hsCRP may provide marginally superior test characteristics and better reflect pathophysiology, the degree of improvement may not merit introducing additional complexity.
Limitations
Adults with congenital heart disease have a a wide array of diagnoses and variable underlying pathophysiology. Although this represents one of the largest prospective biomarker studies performed in this population, and we analysed the data for major pathophysiology subsets (e.g. Fontan vs. bi-ventricular), the absolute numbers of patients and events for most relevant diagnoses did not allow us to perform subgroup analyses to test whether the findings overall were equivalent between diagnoses. We did not measure other established and emerging cardiovascular biomarkers such as high-sensitivity troponin, galectin-3, growth differentiation factor 15 (GDF-15), soluble suppression of tumorigenicity-2 (ST2), and N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) [23] [24] [25] ; it remains unknown whether the association between hsCRP levels and outcomes would be independent of the information provided by other biomarkers. That said, the pathophysiology underlying elevated hsCRP differs from other clinical cardiovascular biomarkers, and studies in other populations have suggested a weak correlation between levels of hsCRP and these markers. 26 CRP is also elevated as part of the acute phase response to infection. Markedly elevated levels might reflect active infection rather than stable, chronic inflammation. This is unlikely to have accounted for our findings, however. First, sensitivity analysis excluding patients with markedly elevated levels did not appreciably alter the results. Second, we did not observe any cases of endocarditis or other acute infections over the month following hsCRP measurement in the cohort, including among those with values >10 mg/L. Third, such hsCRP elevation due to acute, ephemeral inflammatory processes unrelated to cardiovascular outcomes would more likely bias the results of our analysis, focused mainly on non-elective cardiovascular hospitalizations, towards the null rather than towards a false-positive association.
Implications
Elevated hsCRP, indicative of chronic inflammation, is associated with adverse clinical outcomes in adults with CHD. These findings implicate inflammation in the pathophysiology of deterioration and adverse outcomes among adults with CHD. This observation could have a fundamental impact on our approach to caring for these patients. The underlying mechanisms require further study. It is plausible that better understanding of the causes of inflammation and the pathways by which inflammation results in adverse outcomes may identify pharmacologic targets independent of cardiovascular anatomy or haemodynamic pathophysiology. These results also suggest that measuring hsCRP may help assess risk of adverse events in adults with CHD. From the perspective of risk prediction, defining a clear role for hsCRP in clinical care will require further research to better understand how much prognostic value is added by hsCRP beyond the existing framework of care and risk assessment, the response of hsCRP to changes in clinical status, and identifying interventions that ameliorate the additional risk indicated by elevated hsCRP.
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